CAR T-cell Therapy in Multiple Myeloma: Finding Its Right Place - Episode 3

Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM

,

Experts discuss how they decide between utilizing cilta-cel vs ide-cel in multiple myeloma, considering factors like disease characteristics, patient factors, and product differences, while reviewing the final progression-free survival (PFS) analysis from the KarMMA-3 study with ide-cel and key takeaways from the ASH 2024 update on minimal residual disease (MRD) negativity rates from CARTITUDE-4 with cilta-cel and its impact on clinical practice.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Optimizing CAR T in R/R MM: Treatment Paradigms and Patient Selection
    EP. 2: Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT
    Now Viewing
    EP. 3: Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM
    EP. 4: Strategic Timing for CAR T in R/R MM: The Importance of Early Referral
    EP. 5: Bridging to CAR T in R/R MM: Best Practices
    EP. 6: Explaining CAR T: Key Points for Patient Counseling
    EP. 7: Overcoming Barriers to CAR T Referral in R/R MM
    EP. 8: Collaborative Approach in Managing Post CAR T Care Between Academic and Community Physicians in R/R MM

    Video content above is prompted by the following:

    • How are you deciding between utilizing cilta-cel vs ide-cel, and what factors (disease, patient, and/or product) impact that decision?
    • KarMMA-3 with ide-cel also recently reported its final PFS analysis. What were some highlights of this data, and what areyour impressions so far?
    • There was a recent update from ASH 2024 regarding the MRD negativity rates from CARTITUDE-4 with cilta-cel; what were some of your key takeaways, and have the data impacted your clinical practice?
    x